Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Double-blind, Placebo Controlled, Ascending Dose, Randomized Phase 1B/2A Study, Investigating Safety, Tolerability, PK/PD of FE 203799 in Lymphoma Patients, Undergoing Myeloablative Chemotherapy Before Autologous Transplantation

NCT03417765 is registered in ClinicalTrials.gov with GlyPharma Therapeutics as lead sponsor.

NCT NCT03417765
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03417765 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Double-blind, Placebo Controlled, Ascending Dose, Randomized Phase 1B/2A Study, Investigating Safety, Tolerability, PK/PD of FE 203799 in Lymphoma Patients, Undergoing Myeloablative Chemotherapy Before Autologous Transplantation
Lead sponsor
GlyPharma Therapeutics
Phase
Phase 1/2
Overall status
Withdrawn
Start date
September 1, 2018
Completion date
March 31, 2019
Enrollment
0 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

lymphoma, hodgkin's, adult, lymphoma, non-hodgkin's, adult